In focus · trending topic

FDA-Approval

2 stories · following the connections

Adamas to Host Investor and Analyst Meeting on September 18, 2017

By Nasdaq OMXSep 13, 2017, 8:53 PM UTC

Adamas Announces FDA Approval of GOCOVRI™ as First and Only Medication for the Treatment of Dyskinesia in Parkinson’s Disease Patients

By Nasdaq OMXAug 24, 2017, 8:16 PM UTC